Alzheimer's Research
To learn more about Alzheimer’s, memory loss and ongoing clinical trials in this area, visit our Alzheimer’s Disease Research page.
Learn MoreThe main purpose of this study is to evaluate the safety of LY3954068 in participants with early symptomatic Alzheimer’s Disease (AD). The study will also investigate how much LY3954068 gets into the bloodstream and will test the effects of LY3954068 on markers of AD.
Have a gradual and progressive change in memory or ability to think and function for more than 6 months prior to screening
Have a family member or close friend who is with the participant at least 10 hours per week and can participate in study appointments
Have a mini mental state examination (MMSE) score of 18 to 30 at screening
Males who agree to follow contraceptive requirements, or women not of childbearing potential
Have significant disease affecting the brain other than Alzheimer's Disease (AD) that could interfere with this study
Have other serious illnesses that could interfere with this study
Have certain health conditions that prevent them from getting an MRI or positron emission tomography (PET) scan
Have a history of clinically significant back pain, back pathology and/or back injury (for example, degenerative disease, spinal deformity or spinal surgery) that may predispose to complications or technical difficulty with lumbar puncture
To learn more about Alzheimer’s, memory loss and ongoing clinical trials in this area, visit our Alzheimer’s Disease Research page.
Learn MoreTo learn more about neurological disorders and ongoing clinical trials in the area, visit our Neurological Disorders Research page.
A clinical trial helps us learn if a new potential medicine or treatment works and how it works. Clinical trials are also called clinical research studies. To learn more about what to expect when taking part in a clinical trial, visit our Clinical Trial Information page.